BioSpace News Archive

Asha Therapeutics announced today that it has been selected as a BLUE KNIGHT™ company.

The Board of Directors of GE HealthCare Technologies Inc., a leading medical technology, pharmaceutical diagnostics, and digital solutions innovator, declared a cash dividend of $0.03 per share of Common Stock for the third quarter of 2023 payable on November 15, 2023 to all shareholders of record as of October 20, 2023.

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the achievement of two milestones for its xenotransplantation programs in September: the second transplant of a UHeart™ xenoheart into a living person, and a 61-day study of the UThymoKidney™ xenokidney and thymus in a human pre-clinical model.

GeneDx announced that, effective as of October 1, the compensation committee of GeneDx’s board of directors granted newly-hired employees 133,998 restricted stock units as inducements material to each employee entering into employment with GeneDx.

Skanska has signed an additional contract with Orlando Health to build a hospital in Lakeland, Florida, USA.

ImageBiopsy Lab and Radiobotics have teamed up to advance the use of Artificial-Intelligence supported disease diagnostics for musculoskeletal, orthopaedic, and trauma use-cases in the DACH region.

Vizient, Inc. today announced 2023’s top performers in clinical quality and supply chain excellence.

Arch Biopartners Inc. , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced that it has submitted applications to the Ministry of Health (MoH) and local Ethics Committee in Turkey to obtain permission to proceed with a Phase II trial for LSALT peptide, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).

Bristol Myers Squibb Announces Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer.

Rhythm Pharmaceuticals, Inc. today announced four oral presentations at the 61st Annual European Society for Paediatric Endocrinology (ESPE) Meeting being held September 21-23, 2023 in The Hague, Netherlands.